Seres Therapeutics (MCRB) Misses Q3 EPS by 25c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.33), $0.25 worse than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• AI/ML Innovations plans $2M private placement on the CSE
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c